ESMO Virtual Congress 2020 RCC In-depth

Gene Signatures are Potential Biomarkers for ccRCC

Several gene signatures were associated with outcomes among patients with advanced clear cell RCC, but not non-clear cell RCC.

Gene Expression Signatures May be Predictive for Nivolumab in ccRCC

Gene signatures were identified as potential predictive biomarkers for outcomes with nivolumab among patients with advanced ccRCC in an analysis of the NIVOREN GETUG-AFU 26 trial.

ctDNA Concordant with Tissue Genomic Analysis in RCC

Circulating tumor DNA analysis of genomic alterations was concordant with tissue genomic analysis in a cohort of patients with advanced RCC.

Atezolizumab Plus Cabozantinib Shows Promising Early Results in ccRCC

Atezolizumab plus cabozantinib was tolerable and demonstrated antitumor activity in patients with treatment-naïve, advanced ccRCC, according to a phase 1b study.

Nivolumab Plus Ipilimumab Improves Outcomes in Nephrectomy-Ineligible Advanced RCC

Treatment of patients with aRCC who are ineligible for nephrectomy with nivolumab plus ipilimumab improved outcomes compared with sunitinib, in a post hoc analysis of CheckMate 214.

Gene Signatures May Predict Response to Combination ICIs in ccRCC

Gene signatures were associated with response rate to nivolumab plus ipilimumab among patients with ccRCC, according to results of a phase 2 trial.